Cosmo Pharmaceuticals N.V (C43) — Free Cash Flow Generation Index

Latest as of June 2022: 1.18x

Cosmo Pharmaceuticals N.V (C43) has a Free Cash Flow Generation Index of 1.18x as of June 2022. Free cash flow of €7.39 Million represents 1% of operating cash flow (€6.28 Million). See Cosmo Pharmaceuticals N.V (C43) working capital ratio to evaluate short-term liquidity relative to the company's equity base.

FCF Generation Index

1.18x
Free Cash Flow / Operating CF

Free Cash Flow

€7.39 Million
EUR

Operating Cash Flow

€6.28 Million
EUR

Capital Expenditures

€1.11 Million
EUR

Cosmo Pharmaceuticals N.V Free Cash Flow Generation Index (2016–2024)

Historical FCF Generation Index trend for Cosmo Pharmaceuticals N.V across 6 annual periods. Explore C43 cash flow to debt ratio to assess how comfortably operating cash covers total debt obligations.

Annual Free Cash Flow Generation for Cosmo Pharmaceuticals N.V (2016–2024)

Year-by-year Free Cash Flow Generation Index for Cosmo Pharmaceuticals N.V. For the full company profile including market capitalisation, see Cosmo Pharmaceuticals N.V (C43) total market value.

Year FCG Index Free Cash Flow (EUR) Operating CF Capital Expenditures YoY Change
2024 0.97x €156.76 Million €162.41 Million €5.65 Million ▲ +77.2%
2023 0.54x €18.31 Million €33.62 Million €15.31 Million ▼ -30.2%
2022 0.78x €25.92 Million €33.23 Million €7.31 Million ▲ +139.5%
2021 0.33x €4.11 Million €12.61 Million €5.49 Million ▼ -13.7%
2020 0.38x €4.90 Million €12.98 Million €4.12 Million ▼ -79.6%
2016 1.85x €40.12 Million €21.69 Million €18.43 Million
FCG Index = Free Cash Flow / Operating Cash Flow. FCF = Operating CF + Capital Expenditures (capex stored negative).